Top Companies in Urinalysis Market

The urinalysis market is valued at an estimated USD 4.30 billion in 2024 and is projected to reach USD 6.81 billion by 2029 at a CAGR of 9.6% during the forecast period. Growth in the urinalysis market is mainly driven by factors such as the increasing burden of urinary tract infections (UTIs), diabetes, and kidney & liver diseases and the increasing adoption of PoC tests.

Growing geriatric population in the world is another key factor driving the demand of the urine tests market. The geriatric population is more vulnerable to different types of urinary conditions, such as chronic kidney disease (CKD), and urinary tract infections (UTIs), which needs continued monitoring and detection at an early stage. Urine test proves to be an important diagnostic tool for these health conditions. Moreover, the increasing number of elderly people globally is likely to play a major role in the demand for routine urine test, thus fueling market growth.

To know about the assumptions considered for the study download the pdf brochure

The growing popularity of point-of-care (POC) testing has enhanced the availability of urine diagnostics. They offer quick test results, which allow patients to conduct tests from home or out-of-lab locations. Such ease has given rise to home healthcare solutions and increased demand, thus fueling growth of the urine diagnostics market.

The increased emphasis on preventive care and the detection of disease at an early stage is responsible for the growing use of urine analysis. As the awareness of the need to go for regular health check up increases, more people are opting for diagnostic tests, including urine analysis, as a routine part of their health check up. This trend toward preventive health is going to have a major impact on the demand for urine analysis, adding further to the overall growth of the market.

The key players in this market are Siemens Healthineers AG (Germany), F. Hoffmann-La Roche Ltd (Switzerland), Cardinal Health Inc. (US), Abbott (US), Danaher Corporation (US), Sysmex Corporation (Japan), Thermo Fisher Scientific Inc. (US), QuidelOrtho Corporation (US), Becton, Dickinson and Company (US), Bio-Rad Laboratories, Inc. (US), EKF Diagnostics Holdings plc (UK), ARKRAY, Inc. (Japan), ACON Laboratories, Inc. (US), 77 Elektronika Kft. (Hungary), URIT Medical Electronic Co., Ltd. (China), DIRUI INDUSTRIAL CO., LTD. (China), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), BIOBASE Group (China), Erba Mannheim (UK), Alphatec Scientific E.I.R.L. (Peru), Teco Diagnostics (US), Analyticon Biotechnologies GmbH (Germany), Bioway Biological Technology Co., Ltd. (China), High Technology, Inc. (US), Agappe Diagnostics Ltd. (India), TOYOBO CO., LTD. (Japan), DIALAB GmbH (Austria), Quantimetrix (US), BioCare Corporation (Taiwan), Randox Laboratories Ltd. (Ireland), PZ Cormay S.A. (Poland), YD Diagnostics (South Korea), CONTEC MEDICAL SYSTEMS CO., LTD. (China), Biopanda Reagents Ltd. (UK), Clarity Diagnostics, LLC (US) and Genuine Biosystem Pvt Ltd. (India).

In 2023, Siemens Healthineers AG (Germany) dominated the urinalysis market. The company's global presence and wide range of products have been major contributors to its leadership. Siemens Healthineers focuses greatly on innovation through massive investments in research and development. To further consolidate its position in the market, the company makes strategic partnerships, collaborations, and expansions. Through collaborations with new companies, Siemens Healthineers strengthens its current segments and adds innovative technologies and products. For instance, in November 2024, Siemens Healthineers (Germany) and The Ohio State Wexner Medical Center (US) strengthened their long-term research partnership by entering into a 10-year collaboration aimed at developing clinical care innovations.

In 2023, F. Hoffmann-La Roche Ltd. (Switzerland) held a high market share in the urinalysis market. Roche has a strong position in the biochemical urinalysis market because it has a wide product range of urine analyzers and test strips. Additionally, Roche is committed to innovation to keep its market share and heavily invests in R&D activities. The market position of the company can be credited to its robust sales and distribution network globally, which allows it to sell its products in different countries effectively.

In 2023, Cardinal Health (US) was a dominant player in the urinalysis market. The company generates a substantial percentage of its revenue from the US markets. The company is committed to increasing its self-manufacturing capacity and sourcing capabilities while optimizing its end-to-end global supply chain. For example, in October 2024, the company announced the opening of a new distribution centers in Boylston, Massachusetts, to support its US Medical Products and Distribution business. By undertaking cost-saving initiatives, particularly in its worldwide manufacturing and supply chain, the company achieves considerable savings over the course of the year. Dedicated to long-term expansion, the company seeks both organic growth prospects and strategic investments to expand its capabilities and produce enduring value.

Related Reports:

Urinalysis Market by Product (Consumables (Pregnancy & Fertility Kits, Dipsticks, Disposable, Reagents), Instruments (Automated, Semi-automated, PoC Analyzers)), Test Type (Biochemical, Sediment), Application (UTI, Diabetes) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com